Development and validation of a nomogram including lymphocyte-to-monocyte ratio for initial prostate biopsy: a double-center retrospective study.

Author: Zhong-Han ZHOU ¹ ; Feng LIU ¹ ; Wen-Jie WANG ² ; Xue LIU ³ ; Li-Jiang SUN ¹ ; Yao ZHU ⁴ ; Ding-Wei YE ⁴ ; Gui-Ming ZHANG ¹
Author Information

1. Department of Urology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
2. Department of Special Inspection, Qingdao Eighth People's Hospital, Qingdao 266003, China.
3. Department of Anesthesiology, The Affiliated Hospital of Qingdao University, Qingdao 266003, China.
4. Department of Urology, Fudan University Shanghai Cancer Center, Shanghai 200032, China.
Publication Type:Research Support, Non-U.S. Gov't
Keywords: lymphocyte-to-monocyte ratio; nomogram; prostate biopsy; prostate cancer
From: Asian Journal of Andrology 2021;23(1):41-46
CountryChina
Language:English
Abstract: Here, we developed a prostate cancer (PCa) risk nomogram including lymphocyte-to-monocyte ratio (LMR) for initial prostate biopsy, and internal and external validation were further conducted. A prediction model was developed on a training set. Significant risk factors with P < 0.10 in multivariate logistic regression models were used to generate a nomogram. Discrimination, calibration, and clinical usefulness of the model were assessed using C-index, calibration plot, and decision curve analysis (DCA). The nomogram was re-examined with the internal and external validation set. A nomogram predicting PCa risk in patients with prostate-specific antigen (PSA) 4-10 ng ml